The existence of corruption of TGFβ signaling as a mechanism for malignant progression does not preclude the clinical importance of loss of TGFβ tumor suppressor signaling due to deficiency of receptor expression as a potential target for cancer therapy. Here, TGFB1 is linked to cancer.